Shares of Cuprina Holdings cratered 48.5% to $1.51 on September 16 after the Singapore-based biomedical company priced a deeply discounted stock offering that spooked an already fragile shareholder base. The firm priced a public offering of 4,322,489 Class A ordinary shares at $1.15 per share , a 61% discount to the prior close of $2.93 — a punishing signal that the company could not find buyers anywhere near the market price.
The New Shares Could Flood a Tiny Stock
Cuprina had approximately 2.09 million shares outstanding as of late June. The offering adds 4.32 million new shares — more than doubling the Class A share count in a single stroke. The underwriter also holds a 45-day option to buy up to 648,373 additional shares at the same price , which would push total gross proceeds to roughly $5.72 million . For existing shareholders, each dollar of ownership now represents a significantly smaller slice of the company.
A Company Running on Fumes Needed Cash Fast
Cuprina carries negative equity of about -$4.46 million, with liabilities far exceeding assets . Revenue is tiny at roughly $49,894 — barely enough to cover a month of office rent. The company projected 2026 revenue of just $1.0–$1.5 million and held $3.22 million in cash as of mid-2025. This offering looks less like strategic expansion and more like a company scrambling to keep the lights on, forced to accept fire-sale terms.
FDA Clearance Gave the Stock a Lifeline — This Offering May Have Cut It
Cuprina shares surged over 102% in June after its subsidiary secured FDA clearance for its wound-care maggot therapy . The company also regained Nasdaq compliance in June following a 1-for-8 reverse stock split. But that regulatory momentum is now colliding with brutal dilution math. At $1.51, the stock is approaching its 52-week low of $1.76 (pre-adjusted), and the offering price of $1.15 acts as a new gravitational floor.
The Bottom Line for Investors
Cuprina has small revenue, heavy liabilities, and negative equity. The $4.97 million raised barely dents the balance-sheet hole. Unless management can convert its FDA clearance into real commercial sales quickly, this offering simply bought time — at an enormous cost to shareholders who woke up this morning owning half of what they thought they did.